OMAKASE CONSULTING

📢 𝗧𝗵𝗲 𝗦𝗽𝗮𝗻𝗶𝘀𝗵 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻 (𝗖𝗜𝗣𝗠) 𝗵𝗮𝘀 𝗽𝗿𝗼𝗽𝗼𝘀𝗲𝗱 𝘁𝗵𝗲 𝘁𝗼𝘁𝗮𝗹 𝗼𝗿 𝗽𝗮𝗿𝘁𝗶𝗮𝗹 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 5 𝗻𝗲𝘄 𝗱𝗿𝘂𝗴𝘀 (1 𝙤𝙛 𝙩𝙝𝙚𝙢 𝙤𝙧𝙥𝙝𝙖𝙣 𝙙𝙧𝙪𝙜𝙨) 𝗮𝗻𝗱 𝗮 𝗻𝗲𝘄 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗮 𝗱𝗿𝘂𝗴 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘇𝗲𝗱 𝗮𝗻𝗱 𝗽𝗿𝗲𝘃𝗶𝗼𝘂𝘀𝗹𝘆 𝗳𝗶𝗻𝗮𝗻𝗰𝗲𝗱. ⁣⁣⁣⁣ We are very pleased to share good news for 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗺𝗲𝘁𝗮𝗰𝗵𝗿𝗼𝗺𝗮𝘁𝗶𝗰 𝗹𝗲𝘂𝗸𝗼𝗱𝘆𝘀𝘁𝗿𝗼𝗽𝗵𝘆 (MLD), as a 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 specifically targeting this 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 will now be available in Spain. S͟u͟m͟m͟a͟r͟y͟ ͟o͟f͟ ͟t͟h͟e͟ ͟d͟r͟u͟g͟s͟ ͟r͟e͟i͟m͟b͟u͟r͟s͟e͟d͟ ͟i͟n͟ ͟t͟h͟i͟s͟ ͟p͟r͟i͟c͟i͟n͟g͟ ͟c͟o͟m͟i͟s͟s͟i͟o͟n͟:͟   • 𝗟𝗶𝗯𝗺𝗲𝗹𝗱𝘆 (atidarsagen autotemcel): Gene therapy for MLD characterized by mutations in the ARSA gene, leading to reduced ARSA enzyme activity:  - In children with late-infantile or early-juvenile forms without clinical manifestations of the disease. - In children with early-juvenile forms showing initial clinical symptoms, who can still walk independently and have not yet experienced cognitive decline.   • 𝗧𝗲𝗽𝗸𝗶𝗻𝗹𝘆 (epcoritamab): Monotherapy for adult patients with relapsed or refractory DLBCL after two or more lines of systemic treatment.   • 𝗧𝗮𝗹𝘇𝗲𝗻𝗻𝗮 (talazoparib): In combination with enzalutamide for adult patients with mCRPC where chemotherapy is not clinically indicated.   • 𝗗𝗲𝘀𝗳𝗹𝘂𝗿𝗮𝗻𝗼 𝗕𝗮𝘅𝘁𝗲𝗿 (desflurane): Inhalation agent for maintaining general anesthesia in hospitalized and outpatient surgeries for adults, adolescents, and intubated children. Its use is restricted to situations where no other anesthetic is medically viable.   • 𝗧𝗲𝘃𝗶𝗺𝗯𝗿𝗮 (tislelizumab): - In combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with NSCLC expressing PD-L1 in ≥50% of tumor cells, without EGFR or ALK mutations, who have locally advanced NSCLC unsuitable for surgery or platinum-based chemoradiation, or metastatic NSCLC. - In combination with carboplatin and paclitaxel or nab-paclitaxel for first-line treatment of adult patients with squamous NSCLC that is locally advanced or metastatic and unsuitable for surgical resection or platinum-based chemoradiation. - As monotherapy for adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy. Patients with EGFR-mutated or ALK-positive NSCLC must have also received targeted therapies before tislelizumab. - As monotherapy for adult patients with unresectable, locally advanced, or metastatic ESCC after prior platinum-based chemotherapy.   • 𝗩𝘆𝗱𝘂𝗿𝗮 (rimegepant): Acute treatment of migraine, with or without aura, in adults (new indication).   Link: https://lnkd.in/dejK9NjX #Pharmaceuticals #Pricing #MarketAccess #CIPM #Spain

📢Meet us at ISPOR Europe 2024📢 We are pleased to share that Omakase Consulting will be attending ISPOR Europe 2024. We will be happy to connect with you during the upcomming days. We are proud to share the following projects that will be presented at the congress which have been developed with our collaboration: ⛩ Patient Journey Mapping of the Gene Therapy in haemophilia B in Spain: The Bhemogen project – Monday 18th November. Link to abstract: https://lnkd.in/d2GNzjTT ⛩ Optimizing Management and Outcomes of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in Spain: BEWAYAPDS Project – Tuesday 19th November. Link to abstract: https://lnkd.in/dc_3V46N ⛩Value contribution of etranacogene dezaparvovec for the treatment of severe and moderately severe Haemophilia B in Spain through Multicriteria Decision Analysis (MCDA) - Tuesday 19th November. Link to abstract: https://lnkd.in/dwE5RrkJ ⛩ Cost-Effectiveness of Atidarsagene Autotemcel (arsa-cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in Spain - Tuesday 19th November. Link to abstract: https://lnkd.in/dJMuAwPq ⛩ A Multi-Criteria Decision Analysis (MCDA) to Determine the Value of Recombinant ADAMTS3 Vs Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) in Spain – Wednesday 20th November. Link to abstract: https://lnkd.in/d2pTnucg hashtag #ISPOREurope #HEOR #MarketAccess #Omakase #PatientAccess #AccessSolutions

📢 𝗡𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 (𝗧𝗣𝗥𝘀) 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗦𝗽𝗮𝗶𝗻:⁣⁣ ⁣ - 𝗣𝗲𝗺𝗯𝗿𝗼𝗹𝗶𝘇𝘂𝗺𝗮𝗯 (Keytruda®) in combination with chemotherapy with or without blevacizumab in the treatment of persistent, recurrent or metastatic cervical cancer. ⁣ ⁣ Link:⁣ https://lnkd.in/dymKGujP ⁣ - 𝗧𝗮𝗹𝗮𝘇𝗼𝗽𝗮𝗿𝗶𝗯 (Talzenna®) in combination with enzalutamide, for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated. ⁣ ⁣ Link: ⁣https://lnkd.in/dJ7-d5zM ⁣ - 𝗣𝗲𝗴𝗰𝗲𝘁𝗮𝗰𝗼𝗽𝗹𝗮𝗻 (Aspaveli®) in monotherapy in the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) presenting with hemolytic anemia. ⁣ ⁣ Link: ⁣https://lnkd.in/dpMYeHPK ⁣ - 𝗕𝗲𝗺𝗽𝗲𝗱𝗼𝗶𝗰 𝗮𝗰𝗶𝗱 (Nilemdo®) and bempedoic acid with ezetimibe (Nustendi®) in primary hypercholesterolemia (familial and non-familial heterozygous) or mixed dyslipemia, and in adults with established or high-risk atherosclerotic cardiovascular disease, to reduce cardiovascular risk by lowering C-LDL levels. ⁣ ⁣ Link: ⁣https://lnkd.in/dS6nXxEh ⁣ - 𝗢𝗻𝗮𝘀𝗲𝗺𝗻𝗼𝗴𝗲𝗻𝗲 𝗮𝗯𝗲𝗽𝗮𝗿𝘃𝗼𝘃𝗲𝗰 (Zolgensma®) in the treatment of patients with spinal muscular atrophy (SMA) at 5q with a biallelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with SMA at 5q with a biallelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. ⁣ ⁣ Link: https://lnkd.in/d53V7Qzy ⁣ #Pharmaceuticals #AEMPS #TPRs #MarketAccess #Spain

📢 𝗧𝗼𝗱𝗮𝘆, 𝗢𝗺𝗮𝗸𝗮𝘀𝗲 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗶𝗻𝗴 𝗵𝗮𝗱 𝘁𝗵𝗲 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗺𝗼𝗱𝗲𝗿𝗮𝘁𝗲 𝗮 𝗿𝗼𝘂𝗻𝗱 𝘁𝗮𝗯𝗹𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝘁𝗶𝘁𝗹𝗲𝗱 "𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙞𝙣𝙜 𝙎𝙩𝙧𝙖𝙩𝙚𝙜𝙮, 𝘼𝙙𝙫𝙤𝙘𝙖𝙘𝙮, 𝙖𝙣𝙙 𝙋𝙖𝙧𝙩𝙣𝙚𝙧𝙞𝙣𝙜 𝙛𝙤𝙧 𝙊𝙧𝙥𝙝𝙖𝙣 𝘿𝙧𝙪𝙜𝙨 𝙞𝙣 𝙎𝙥𝙖𝙞𝙣" 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗻𝘁𝗲𝘅𝘁 𝗼𝗳 W𝗼𝗿𝗹𝗱 𝗢𝗿𝗽𝗵𝗮𝗻 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀. ⁣ ⁣ We were delighted to host a panel of experts representing the Ministry of Health, the Spanish Medicines Agency, the Catalonian Healthcare Government, the pharmaceutical industry, the ORPHAR-SEFH coordinator, and the president of the Haemophilia Patient Association (Fedhemo). ⁣ ⁣ Each expert shared their insights in light of 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗮𝗻𝗱 𝗦𝗽𝗮𝗻𝗶𝘀𝗵 𝗥𝗼𝘆𝗮𝗹 𝗗𝗲𝗰𝗿𝗲𝗲 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 concerning orphan medicines. The discussions highlighted how Spain is already implementing a strategic roadmap and working in collaboration to deliver much-needed therapies to patients suffering from rare diseases.⁣ ⁣ This is a clear example of partnership and progress on a practical level as we await the full deployment of the new regulations.⁣ ⁣ ⁣ #WODC24 #RareDiseases #OrphanDrugs #Advocacy #Spain

📢 𝗧𝗵𝗲 𝗦𝗽𝗮𝗻𝗶𝘀𝗵 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻 (𝗖𝗜𝗣𝗠) 𝗵𝗮𝘀 𝗽𝗿𝗼𝗽𝗼𝘀𝗲𝗱 𝘁𝗵𝗲 𝘁𝗼𝘁𝗮𝗹 𝗼𝗿 𝗽𝗮𝗿𝘁𝗶𝗮𝗹 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝟲 𝗻𝗲𝘄 𝗱𝗿𝘂𝗴𝘀 (𝟯 𝙤𝙛 𝙩𝙝𝙚𝙢 𝙤𝙧𝙥𝙝𝙖𝙣 𝙙𝙧𝙪𝙜𝙨) 𝗮𝗻𝗱 𝗻𝗲𝘄 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝟮 𝗱𝗿𝘂𝗴𝘀, 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘇𝗲𝗱 𝗮𝗻𝗱 𝗽𝗿𝗲𝘃𝗶𝗼𝘂𝘀𝗹𝘆 𝗳𝗶𝗻𝗮𝗻𝗰𝗲𝗱. ⁣⁣⁣⁣ ⁣ - 𝗔𝗹𝘁𝘂𝘃𝗼𝗰𝘁 𝘏* (efanesoctocog alfa): treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency). It can be used in all age groups.⁣ ⁣ - 𝗙𝗿𝘂𝘇𝗮𝗾𝗹𝗮 (fruquintinib): treatment of adult patients with metastatic colorectal cancer (mCRCC) who have previously been treated with standard available therapies, such as fluoropyrimidine-based chemotherapy, oxaliplatin and irinotecan, anti-VEGF and anti-EGFR drugs and who have progressed or are intolerant to treatment with trifluridine-tipiracil or regorafenib.⁣ ⁣ - 𝗧𝗮𝗹𝘃𝗲𝘆 𝘏* (talquetamab): monotherapy treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior treatments, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have had disease progression to the last treatment.⁣ ⁣ - 𝗘𝗹𝘂𝗰𝗶𝗿𝗲𝗺 (gadopiclenol): indicated in adults and children 2 years of age and older for contrast-enhanced magnetic resonance imaging (MRI) to enhance the detection and visualization of pathologies with blood-brain barrier (BBB) disruption and/or abnormal vascularity of brain, spine and associated central nervous system (CNS) tissues, liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system. 𝘐𝘵 𝘴𝘩𝘰𝘶𝘭𝘥 𝘰𝘯𝘭𝘺 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘸𝘩𝘦𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯 𝘪𝘴 𝘦𝘴𝘴𝘦𝘯𝘵𝘪𝘢𝘭, 𝘢𝘯𝘥 𝘪𝘴 𝘯𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘸𝘪𝘵𝘩 𝘶𝘯𝘦𝘯𝘩𝘢𝘯𝘤𝘦𝘥 𝘔𝘙𝘐.⁣ ⁣ - 𝗥𝗲𝘇𝘇𝗮𝘆𝗼 𝘏* (rezafungin): treatment of invasive candidiasis in adults.⁣ ⁣ - 𝗟𝗼𝗷𝘂𝘅𝘁𝗮 (lomitapide): treatment as an adjunct to a low-fat diet and other lipid-lowering drugs with or without low-density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH).⁣ ⁣ 𝘏*: orphan drug. ⁣ ⁣ 🔎N𝗲𝘄 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗳𝘂𝗻𝗱𝗲𝗱 𝗱𝗿𝘂𝗴𝘀:⁣ ⁣ - 𝗕𝗲𝘆𝗳𝗼𝗿𝘁𝘂𝘀 (nirsevimab): prevention of lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in children up to 24 months of age who remain vulnerable to severe RSV disease during their second RSV season.⁣ ⁣ - 𝗢𝗺𝗻𝗶𝗽𝗮𝗾𝘂𝗲 (iohexol): determination of glomerular filtration rate (GFR) in the assessment of renal function in adults and children.⁣ ⁣ ⏫ 𝗔𝗹𝘀𝗼, 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗮𝗴𝗿𝗲𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝘅𝘁𝗲𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴𝘀: 𝗜𝗺𝗰𝗶𝘃𝗿𝗲𝗲 (setmelanotida) and 𝗥𝗼𝘇𝗹𝘆𝘁𝗿𝗲𝗸 (entrectinib). ⁣ Link: https://lnkd.in/dZKaFdpK ⁣ ⁣#Pharmaceuticals #Pricing #MarketAccess #CIPM #Spain

📢 W𝗲 𝗮𝗿𝗲 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘁𝗵𝗮𝘁 𝗗𝗿. 𝗫𝗮𝘃𝗶𝗲𝗿 𝗕𝗮𝗱𝗶𝗮 𝗵𝗮𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝗮 𝘁𝗮𝗹𝗸 𝘁𝗵𝗶𝘀 𝗮𝗳𝘁𝗲𝗿𝗻𝗼𝗼𝗻 𝗼𝗻 "𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘢𝑝𝑝𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘵𝘰 𝘴𝘶𝑝𝑝𝘰𝘳𝘵 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘢𝘥𝘷𝘢𝘯𝘤𝘦 𝘵𝘩𝘦𝘳𝘢𝑝𝘪𝘦𝘴: 𝘔𝘶𝘭𝘵𝘪𝘤𝘳𝘪𝘵𝘦𝘳𝘪𝘢 𝘋𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘈𝘯𝘢𝘭𝘺𝘴𝘪𝘴" 𝗮𝘁 𝘁𝗵𝗲 W𝗼𝗿𝗹𝗱 𝗢𝗿𝗽𝗵𝗮𝗻 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀, which is currently taking place in Barcelona. ⁣ ⁣ It was an insightful session on this methodology, which facilitates multidisciplinary decision-making and access to advanced therapies. ⁣ ⁣ Don't miss the opportunity to meet us in the Booth 60! ⁣ ⁣ ⁣ #WODC24 #MCDA #MarketAccess #GeneTherapies #OrphanDrug #RareDiseases⁣

📢 𝗢𝗺𝗮𝗸𝗮𝘀𝗲 𝗶𝘀 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 𝘆𝗼𝘂 𝗮𝘁 W𝗼𝗿𝗹𝗱 𝗢𝗿𝗽𝗵𝗮𝗻 𝗗𝗿𝘂𝗴!⁣ ⁣ 🤝 Come and visit us in Booth 60! ⁣ ⁣ ⁣ #WODC24 #MarketAccess #Rarediseases #GeneTherapies #HTA

📢 𝗢𝗺𝗮𝗸𝗮𝘀𝗲 𝗵𝗮𝘀 𝘁𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝗵𝗮𝘃𝗲 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 "𝘈𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘊𝘢𝘯𝘤𝘦𝘳 𝘪𝘯 𝘚𝑝𝘢𝘪𝘯: 𝘊𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴 𝘢𝘯𝘥 𝘖𝑝𝑝𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘪𝘯 𝘗𝘳𝘪𝘤𝘪𝘯𝘨, 𝘍𝘶𝘯𝘥𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘏𝘛𝘈 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴", organized by the 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 (ECO) and the 𝗙𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 (Fundamed). ⁣ ⁣ It was an engaging debate on the challenges of 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝗰𝗰𝗲𝘀𝘀 and how the n𝗲𝘄 𝗛𝗧𝗔 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 will shape the 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗶𝗻 𝗦𝗽𝗮𝗶𝗻. ⁣ ⁣ 🚀Exciting times ahead for innovation in 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗮𝗿𝗲! ⁣ ⁣ ⁣ #Pharmaceuticals #Oncology #MarketAccess #HTA #HealthcareInnovation #Spain

📢 𝗥𝗘𝗠𝗘𝗠𝗕𝗘𝗥! ⁣ Next week, on October 24th, Dr. Alicia Gil will be moderating the interesting conference "𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆, 𝗔𝗱𝘃𝗼𝗰𝗮𝗰𝘆 & 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝗶𝗻𝗴 𝗳𝗼𝗿 𝗢𝗿𝗽𝗵𝗮𝗻 𝗗𝗿𝘂𝗴𝘀 𝗶𝗻 𝗦𝗽𝗮𝗶𝗻" at the W𝗼𝗿𝗹𝗱 𝗢𝗿𝗽𝗵𝗮𝗻 𝗗𝗿𝘂𝗴𝘀 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 2024.⁣ ⁣ Don't miss it! ⁣ ⁣ ⁣Link: https://lnkd.in/dtQQckuT ⁣ 🤝 Visit us in Booth 60! ⁣ ⁣ #WODC2024 #OrphanDrugs #RealWorldEvidence #MarketAccess

📢 𝗡𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗿𝗲𝗽𝗼𝗿𝘁𝘀 (𝗧𝗣𝗥𝘀) 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗦𝗽𝗮𝗶𝗻:⁣ ⁣ - 𝗟𝗲𝗯𝗿𝗶𝗸𝗶𝘇𝘂𝗺𝗮𝗯 (Ebglyss®) in Atopic Dermatitis.⁣ ⁣ Link: https://lnkd.in/dEDGQ4Bu - 𝗟𝗼𝗻𝗰𝗮𝘀𝘁𝘂𝘅𝗶𝗺𝗮𝗯 𝘁𝗲𝘀𝗶𝗿𝗶𝗻𝗲 (Zynlonta®) as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGGL) after two or more lines of systemic therapy.⁣ ⁣ Link: https://lnkd.in/dq4z-RP6 - 𝗔𝘃𝗮𝗽𝗿𝗶𝘁𝗶𝗻𝗶𝗯 (Ayvakyt®) in the treatment of adult patients with indolent systemic mastocytosis (MSI) with moderate to severe symptoms inadequately controlled with symptomatic therapy.⁣ ⁣ Link: https://lnkd.in/ddn8UU92 - 𝗖𝗲𝗿𝗹𝗶𝗽𝗼𝗻𝗮𝘀𝗲 𝗮𝗹𝗳𝗮 (Brineura®) in the treatment of neuronal ceroid lipofuscinosis neuronal type 2 (LCN2) disease, also referred to as tripeptidyl-peptidase 1 (TPP1) deficiency. ⁣ ⁣ Link: https://lnkd.in/d_HuJYeq - 𝗥𝗼𝘇𝗮𝗻𝗼𝗹𝗶𝘅𝗶𝘇𝘂𝗺𝗮𝗯 (Rystiggo®) as an adjunct to standard therapy for the treatment of generalized myasthenia gravis in adult patients with positive antibodies to AChR or MuSK.⁣ ⁣ Link: https://lnkd.in/dsF8N4AA #Pharmaceuticals #AEMPS #TPRs #MarketAccess #Spain ⁣ ⁣ ⁣